Matches in SemOpenAlex for { <https://semopenalex.org/work/W2424975101> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2424975101 endingPage "43" @default.
- W2424975101 startingPage "3039" @default.
- W2424975101 abstract "Lung cancer is the leading cause of cancer death in men worldwide; most cases are not suitable for radical surgery at diagnosis and palliative treatment remains the primary goal of therapy. Cisplatin and gemcitabine are among the most active cytotoxic agents for the treatment of non-small cell lung cancer (NSCLC): they have non-overlapping toxicity and preclinical studies have demonstrated their potential synergistic interaction.The aims of the present study were to assess the activity and tolerability of cisplatin 80 mg/m2 on day 1, combined with gemcitabine 1000 mg/m2 on days 1 and 8, administered every 3 weeks. A total of 46 consecutive patients with advanced NSCLC entered this study; all of them were evaluable for toxicity and for activity.According to an intent-to-treat analysis, 15 patients attained a partial response (33%), 9 (20%) obtained a disease stabilisation and 22 (47%) progressed. This regimen appeared to be modestly toxic, with grades 3-4 leukopenia and thrombocytopenia observed in 10% and 6% of cases respectively; grade 3 vomiting appeared in 12 patients (26%) and grade 3 mucositis in 1 patient. The median time-to-progression and overall survival were 200 and 400 days, respectively.Our study of gemicitabine + cisplatin on stage IV NSCLC patients achieved favourable results in terms of toxicity and overall survival." @default.
- W2424975101 created "2016-06-24" @default.
- W2424975101 creator A5002677597 @default.
- W2424975101 creator A5014664627 @default.
- W2424975101 creator A5017893863 @default.
- W2424975101 creator A5034198956 @default.
- W2424975101 creator A5055186277 @default.
- W2424975101 creator A5075637844 @default.
- W2424975101 creator A5084457729 @default.
- W2424975101 date "2003-01-18" @default.
- W2424975101 modified "2023-10-14" @default.
- W2424975101 title "Gemcitabine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a phase II study." @default.
- W2424975101 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12530039" @default.
- W2424975101 hasPublicationYear "2003" @default.
- W2424975101 type Work @default.
- W2424975101 sameAs 2424975101 @default.
- W2424975101 citedByCount "7" @default.
- W2424975101 countsByYear W24249751012012 @default.
- W2424975101 countsByYear W24249751012015 @default.
- W2424975101 countsByYear W24249751012021 @default.
- W2424975101 crossrefType "journal-article" @default.
- W2424975101 hasAuthorship W2424975101A5002677597 @default.
- W2424975101 hasAuthorship W2424975101A5014664627 @default.
- W2424975101 hasAuthorship W2424975101A5017893863 @default.
- W2424975101 hasAuthorship W2424975101A5034198956 @default.
- W2424975101 hasAuthorship W2424975101A5055186277 @default.
- W2424975101 hasAuthorship W2424975101A5075637844 @default.
- W2424975101 hasAuthorship W2424975101A5084457729 @default.
- W2424975101 hasConcept C121608353 @default.
- W2424975101 hasConcept C126322002 @default.
- W2424975101 hasConcept C141071460 @default.
- W2424975101 hasConcept C143998085 @default.
- W2424975101 hasConcept C197934379 @default.
- W2424975101 hasConcept C2776256026 @default.
- W2424975101 hasConcept C2776694085 @default.
- W2424975101 hasConcept C2776907518 @default.
- W2424975101 hasConcept C2778239845 @default.
- W2424975101 hasConcept C2778375690 @default.
- W2424975101 hasConcept C2778496288 @default.
- W2424975101 hasConcept C2780258809 @default.
- W2424975101 hasConcept C2780873365 @default.
- W2424975101 hasConcept C2781413609 @default.
- W2424975101 hasConcept C29730261 @default.
- W2424975101 hasConcept C31760486 @default.
- W2424975101 hasConcept C71924100 @default.
- W2424975101 hasConcept C90924648 @default.
- W2424975101 hasConceptScore W2424975101C121608353 @default.
- W2424975101 hasConceptScore W2424975101C126322002 @default.
- W2424975101 hasConceptScore W2424975101C141071460 @default.
- W2424975101 hasConceptScore W2424975101C143998085 @default.
- W2424975101 hasConceptScore W2424975101C197934379 @default.
- W2424975101 hasConceptScore W2424975101C2776256026 @default.
- W2424975101 hasConceptScore W2424975101C2776694085 @default.
- W2424975101 hasConceptScore W2424975101C2776907518 @default.
- W2424975101 hasConceptScore W2424975101C2778239845 @default.
- W2424975101 hasConceptScore W2424975101C2778375690 @default.
- W2424975101 hasConceptScore W2424975101C2778496288 @default.
- W2424975101 hasConceptScore W2424975101C2780258809 @default.
- W2424975101 hasConceptScore W2424975101C2780873365 @default.
- W2424975101 hasConceptScore W2424975101C2781413609 @default.
- W2424975101 hasConceptScore W2424975101C29730261 @default.
- W2424975101 hasConceptScore W2424975101C31760486 @default.
- W2424975101 hasConceptScore W2424975101C71924100 @default.
- W2424975101 hasConceptScore W2424975101C90924648 @default.
- W2424975101 hasIssue "5" @default.
- W2424975101 hasLocation W24249751011 @default.
- W2424975101 hasOpenAccess W2424975101 @default.
- W2424975101 hasPrimaryLocation W24249751011 @default.
- W2424975101 hasRelatedWork W2024219304 @default.
- W2424975101 hasRelatedWork W2031554341 @default.
- W2424975101 hasRelatedWork W2037716484 @default.
- W2424975101 hasRelatedWork W2147443719 @default.
- W2424975101 hasRelatedWork W2322460005 @default.
- W2424975101 hasRelatedWork W2349270370 @default.
- W2424975101 hasRelatedWork W2361287035 @default.
- W2424975101 hasRelatedWork W2368782604 @default.
- W2424975101 hasRelatedWork W2416376379 @default.
- W2424975101 hasRelatedWork W2424975101 @default.
- W2424975101 hasVolume "22" @default.
- W2424975101 isParatext "false" @default.
- W2424975101 isRetracted "false" @default.
- W2424975101 magId "2424975101" @default.
- W2424975101 workType "article" @default.